ClusterOS Diagnostic Profile

Aberdeen LifeSciences

Aberdeen, United Kingdom Extraction-Intermediary 73 evidence items

Aberdeen LifeSciences runs on 73 evidence items (Aberdeen LifeSciences UKRI grants: 128 grants, £84m total, 8 distinct lead or). The diagnostic resolves a Extraction-Intermediary configuration at HIGH confidence.

9
Active stalls
1
Stacks identified
73
Evidence items
6
Leverage timeline (mo)
S1
Re-proving Instead of Narrowing
low
S2
Coordinating Instead of Deciding
medium
S3
Forgiving Instead of Redesigning
indeterminate
S4
Extracting Without Reinvesting
medium
S5
Mediating Instead of Coupling
low
Stabilising Around Incumbents
high
S7
Narrating Instead of Testing
indeterminate
S8
Scaling Activity Instead of Throughput
medium
S9
Waiting for Permission
indeterminate
Stack 01 S4 · S5 · S6

Incumbents extract value via intermediary relationships; intermediaries protect incumbent access; incumbent stability suppresses the disruption that would reduce extraction.

"If University of Aberdeen published annual data on: (1) PhD graduate destinations (Aberdeen vs. elsewhere), (2) spin-out equity ownership by location, (3) licensing revenue retention vs. distribution, it might reduce the system's ability to absorb success signals without local retention becoming visible as a...

6-12 months

Leverage hypotheses are testable perturbations, not prescriptions. Where demand-side behaviour is weakly visible, the correct move is observation — improving visibility before attempting change.

What happens next
This is a structural profile, not a full diagnostic.

A full ClusterOS diagnostic adds actor questionnaire data, working sessions, and anchor interviews — producing higher-confidence stall identification, board-ready stack analysis, and leverage hypotheses calibrated to your specific context.

Aberdeen LifeSciences
Free Pulse Check → Request a Diagnostic →